Literature DB >> 28494557

[Clinicopathologic features of drug-induced vanishing bile duct syndrome].

L H Ye1, C K Wang2, H C Zhang1, Z Q Liu1, H W Zheng3.   

Abstract

Vanishing bile duct syndrome (VBDS) manifests as progressive destruction and disappearance of the intrahepatic bile duct caused by various factors and cholestasis. VBDS associated with drug-induced liver injury (D-VBDS) is an important etiology of VBDS, and immune disorder or immune imbalance may be the main pathogenesis. According to its clinical symptoms, serological markers, and course of the disease, D-VBDS is classified into major form and minor form, and its clinical features are based on various pathomorphological findings. Its prognosis is associated various factors including regeneration of bile duct cells, number of bile duct injuries, level and range of bile duct injury, bile duct proliferation, and compensatory shunt of bile duct branches. This disease has various clinical outcomes; most patients have good prognosis after drug withdrawal, and some patients may experience cholestatic cirrhosis, liver failure, and even death. Due to the clinical manifestation and biochemical changes are similar to the primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), it need to identify by clinical physician.

Entities:  

Keywords:  Drug induced; Pathogenetic mechanism; Pathology, clinical; Prognosis; Vanishing bile duct syndrome

Mesh:

Year:  2017        PMID: 28494557     DOI: 10.3760/cma.j.issn.1007-3418.2017.04.019

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  2 in total

1.  Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report.

Authors:  Yu Sun; Chen Shao; Hao Qu; Gang Zuo; Tao Jing; Taihu Wan; Shangwei Ji
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

2.  Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.

Authors:  Qian Zhang; Zhiqiang Liu; Shanshan Wu; Weijia Duan; Sha Chen; Xiaojuan Ou; Hong You; Yuanyuan Kong; Jidong Jia
Journal:  Gastroenterol Res Pract       Date:  2019-06-10       Impact factor: 2.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.